メバロン酸は第Xa因子を増強することにより、血液凝固促進効果を発揮する
Liyuan Niu1, Chuanfeng Liu2, Shaoying Wang3
1Department of Vascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, China.
Natural products and bioprospecting
|January 10, 2026
まとめ
メバロン酸(MVA)は第Xa因子(FXa)活性を増強することで血液凝固を促進し、血栓症のリスクを高めます。この脂質経路代謝物は凝固に直接影響を与え、代謝性疾患に対する新たな治療標的を提供します。
科学分野:
- 生化学
- 血液学
- 代謝経路
背景:
- 血栓症の病因には、脂質代謝および炎症が関与する。
- メバロン酸経路の凝固における役割は十分に理解されていない。
研究 の 目的:
- メバロン酸(MVA)の凝固系に対する調節効果を調査する。
- MVAの止血および血栓症に対する直接的な影響を解明する。
主な方法:
- 凝固に対するMVAの効果を決定するための再石灰化アッセイおよび酵素速度論的解析。
- 出血および血栓症のマウスモデルを用いた生体内の研究。
- 天然基質加水分解アッセイによる凝固標的の同定。
主要な成果:
- MVAは第Xa因子(FXa)の血液凝固促進活性を増強することにより、血漿凝固を著しく促進した。
- MVAは活性化部分トロンボプラスチン時間およびプロトロンビン時間を短縮し、出血時間を短縮した。
- MVA投与は、塩化第二鉄誘発血栓症、深部静脈血栓症、および脳梗塞モデルにおいて血栓形成を増強した。
結論:
- メバロン酸はFXaの血液凝固促進活性を直接調節し、脂質代謝と凝固を結びつける。
- 本研究結果は、脂質代謝と炎症シグナル伝達の間のクロストークが凝固に関与していることを示唆している。
- メバロン酸経路は、代謝性疾患における血栓症合併症の潜在的な治療標的を表す。
関連する概念動画
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Extrinsic and Intrinsic Pathways of Hemostasis
11.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.9K
Venous Thrombosis III: Interprofessional Care
273
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
273
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
EDTA: Auxiliary Complexing Reagents
1.3K
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
1.3K


